当前位置: 首页 >> 检索结果
441. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
To evaluate the safety and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule, after 1, 3, and 6 months.
442. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease.
作者: A P Kennedy.;E Nelson.;D Reeves.;G Richardson.;C Roberts.;A Robinson.;A E Rogers.;M Sculpher.;D G Thompson.
来源: Gut. 2004年53卷11期1639-45页
We developed a patient centred approach to chronic disease self management by providing information designed to promote patient choice. We then conducted a randomised controlled trial of the approach in inflammatory bowel disease (IBD) to assess whether it could alter clinical outcome and affect health service use.
443. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
作者: W Kruis.;P Fric.;J Pokrotnieks.;M Lukás.;B Fixa.;M Kascák.;M A Kamm.;J Weismueller.;C Beglinger.;M Stolte.;C Wolff.;J Schulze.
来源: Gut. 2004年53卷11期1617-23页
Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis.
444. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel.
The mucosa associated flora of the large intestine is important in determining mucosal function although what controls its composition is unknown. This study has determined the effect of the prebiotic carbohydrates oligofructose and inulin on the mucosal flora.
445. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial.
作者: W Voskuijl.;F de Lorijn.;W Verwijs.;P Hogeman.;J Heijmans.;W Mäkel.;J Taminiau.;M Benninga.
来源: Gut. 2004年53卷11期1590-4页
Recently, polyethylene glycol (PEG 3350) has been suggested as a good alternative laxative to lactulose as a treatment option in paediatric constipation. However, no large randomised controlled trials exist evaluating the efficacy of either laxative.
446. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
作者: W J Sandborn.;B G Feagan.;G Radford-Smith.;A Kovacs.;R Enns.;A Innes.;J Patel.
来源: Gut. 2004年53卷10期1485-93页
Targeting tumour necrosis factor alpha (TNF-alpha) has demonstrated efficacy in Crohn's disease.
447. Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome.
Visceral hypersensitivity has been evidenced in patients with irritable bowel syndrome (IBS) but its mechanisms remain poorly elucidated. We investigated the spinal transmission of nociceptive signals in IBS patients by analysing the effects of rectal distensions on electromyographic recordings of the somatic nociceptive flexion (RIII) reflex, an objective index of spinal nociceptive processes.
448. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial.
Patients with irritable bowel syndrome (IBS) often feel they have some form of dietary intolerance and frequently try exclusion diets. Tests attempting to predict food sensitivity in IBS have been disappointing but none has utilised IgG antibodies.
449. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
作者: G Hoff.;T Grotmol.;E Thiis-Evensen.;M Bretthauer.;G Gondal.;M H Vatn.
来源: Gut. 2004年53卷9期1329-33页
Screening for colorectal cancer (CRC) using guaiac based faecal occult blood tests (FOBT) has an estimated programme sensitivity of >60% but <30% for strictly asymptomatic CRC in a single screening round. In search for improved non-invasive tests for screening, we compared a test for faecal calprotectin (PhiCal) with a human haemoglobin immunochemical FOBT (FlexSure OBT).
450. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication.
作者: W K Leung.;S-R Lin.;J Y L Ching.;K-F To.;E K W Ng.;F K L Chan.;J Y W Lau.;J J Y Sung.
来源: Gut. 2004年53卷9期1244-9页
Gastric intestinal metaplasia (IM) is generally considered to be a precancerous lesion in the gastric carcinogenesis cascade. This study identified the risk factors associated with progression of IM in a randomised control study.
451. Sexual and physical abuse are not associated with rectal hypersensitivity in patients with irritable bowel syndrome.
作者: Y Ringel.;W E Whitehead.;B B Toner.;N E Diamant.;Y Hu.;H Jia.;S I Bangdiwala.;D A Drossman.
来源: Gut. 2004年53卷6期838-42页
Patients with irritable bowel syndrome (IBS) have reduced pain thresholds for rectal distension. In addition, the prevalence of sexual/physical abuse in referred IBS patients is high and is associated with greater pain reporting, poorer health status, and poorer outcome. This lead to a hypothesis that abuse history may sensitise patients to report pain at a lower threshold.
452. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial.
作者: M Hage.;P D Siersema.;H van Dekken.;E W Steyerberg.;J Haringsma.;W van de Vrie.;T E Grool.;R L P van Veen.;H J C M Sterenborg.;E J Kuipers.
来源: Gut. 2004年53卷6期785-90页
Photochemical and thermal methods are used for ablating Barrett's oesophagus (BO). The aim of this study was to compare 5-aminolevulinic acid induced photodynamic therapy (ALA-PDT) with argon plasma coagulation (APC) with respect to complete reversal of BO.
453. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction.
作者: H Isayama.;Y Komatsu.;T Tsujino.;N Sasahira.;K Hirano.;N Toda.;Y Nakai.;N Yamamoto.;M Tada.;H Yoshida.;Y Shiratori.;T Kawabe.;M Omata.
来源: Gut. 2004年53卷5期729-34页
Covered self-expandable metal stents (EMS) were recently developed to overcome tumour ingrowth in conventional EMS. However, supporting evidence for the efficacy of covered EMS is lacking.
454. Oats to children with newly diagnosed coeliac disease: a randomised double blind study.
作者: L Högberg.;P Laurin.;K Fälth-Magnusson.;C Grant.;E Grodzinsky.;G Jansson.;H Ascher.;L Browaldh.;J-A Hammersjö.;E Lindberg.;U Myrdal.;L Stenhammar.
来源: Gut. 2004年53卷5期649-54页
Treatment of coeliac disease (CD) requires lifelong adherence to a strict gluten free diet (GFD) which hitherto has consisted of a diet free of wheat, rye, barley, and oats. Recent studies, mainly in adults, have shown that oats are non-toxic to CD patients. In children, only open studies comprising a small number of patients have been performed.
455. Randomised controlled trial of long term portographic follow up versus variceal band ligation following transjugular intrahepatic portosystemic stent shunt for preventing oesophageal variceal rebleeding.
作者: D Tripathi.;H F Lui.;A Helmy.;K Dabos.;E Forrest.;A J Stanley.;R Jalan.;D N Redhead.;P C Hayes.
来源: Gut. 2004年53卷3期431-7页
Transjugular intrahepatic portosystemic stent shunt (TIPSS) is effective in the prevention of variceal rebleeding but requires invasive portographic follow up. This randomised controlled trial aims to test the hypothesis that combining variceal band ligation (VBL) with TIPSS can obviate the need for long term TIPSS surveillance without compromising clinical efficacy, and can reduce the incidence of hepatic encephalopathy.
456. Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy.
Diminutive and flat colorectal lesions can be difficult to detect using conventional colonoscopic techniques. Previous data have suggested that pan-chromoscopy may improve detection rates. No randomised control trial has been performed examining detection rates of such lesions while controlling for extubation time and lavage effect.
457. Randomised clinical trial of synbiotic therapy in elective surgical patients.
It is possible to manipulate the composition of the gastrointestinal microflora by administration of pre- and probiotics. This may help to preserve gut barrier function and reduce the incidence of septic morbidity.
458. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.
作者: J C Y Wu.;F K L Chan.;J Y L Ching.;W-K Leung.;Y Hui.;R Leong.;S C S Chung.;J J Y Sung.
来源: Gut. 2004年53卷2期174-9页
The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease (GORD) is controversial. We hypothesised that H pylori eradication leads to worsened control of reflux disease.
459. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
作者: P J Thuluvath.;A Maheshwari.;J Mehdi.;K D Fairbanks.;L L-W Wu.;L G Gelrud.;M J Ryan.;F A Anania.;I F Lobis.;M Black.
来源: Gut. 2004年53卷1期130-5页
In this study, we compared the efficacy of triple therapy (interferon alfa, ribavirin, and amantadine) with standard therapy (interferon alfa and ribavirin) in treatment naïve patients with chronic hepatitis C virus (HCV).
460. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
作者: T Mimura.;F Rizzello.;U Helwig.;G Poggioli.;S Schreiber.;I C Talbot.;R J Nicholls.;P Gionchetti.;M Campieri.;M A Kamm.
来源: Gut. 2004年53卷1期108-14页
Ten to 15% of patients with pouchitis experience refractory or recurrent disease. The aim of this study was to evaluate the effectiveness of a single daily high dose probiotic preparation (VSL#3) in maintaining antibiotic induced remission, and quality of life (QOL), for one year in such patients.
|